Review
Open access
Sep 2026
Recorded Adoption of SGLT2 Inhibitors from 2022 to 2025 Among Adults with an EHR-Defined HFrEF Phenotype at a Jordanian Public Hospital
Background/Objectives: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are foundational therapy for heart failure with reduced ejection fraction (HFrEF), irrespective of diabetes. We evaluated recorded SGLT2i adoption and diabetes-related differences among adults with an electronic health record (EHR)-defined HFrEF...
Tala Bassam Al-Bawalsah, Anas Abed, Alhareth Ahmad et al.
· Journal of Clinical Medicine · 0 citations